Stay in Step With Treatments for Restless Legs Syndrome

July 2025

Dopamine agonists (ropinirole, etc) are no longer first-line for restless legs syndrome (RLS)...according to the Am Acad of Sleep Medicine.

Now guidelines conditionally recommend AGAINST their use unless patients are prioritizing short-term benefits over long-term risks.

That’s because evidence shows they’re linked to risks with long-term use including augmentation...or the worsening of symptoms.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote